Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease

Clinical Rheumatology

Volumn 29, Issue 10, 2010, Pages 1167-1168

  Koutroumpas, Athanasios ^a   Ziogas, Athanasios ^a   Alexiou, Ioannis ^a   Barouta, Georgia ^a   Sakkas, Lazaros I ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Interstitial lung disease; Mycophenolate mofetil; Systemic sclerosis

Indexed keywords

DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AGED; ARTICLE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VITAL CAPACITY;

AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 79952109158     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-010-1498-z     Document Type: Article

References (14)

1. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:940-944
2. Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E et al (2007) A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral lowdose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 25:169-171
3. Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-Associated interstitial lung disease. Chest 133:455-460
4. Liossis SNC, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 45:1005-1008
5. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR et al (2008) Use of mycophenolate mofetil to treat scleroderma-Associated interstitial lung disease. Respir Med 102:150-155
6. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655-2666
7. Tashkin DT, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026-1034
8. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C et al (2009) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49:271-280. doi:10.1093/ rheumatology/kep093
9. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ et al (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578-583
10. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM (2008) Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology 47:735-737
11. Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P et al (2009) A novel therapeutic approach to the treatment of scleroderma-Associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology 48:49-52
12. Greenwald GI, Tashkin DP, Gong H, Simmons M, Duann S, Furst DE et al (1987) Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis: prospective study. Am J Med 83:83-92
13. Steen VD, Conte C, Owens GR, Medsger TA (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283-1289
14. Steen VD, Owens GR, Redmond C, Rodnan GP, Medsger TA (1985) The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 20:882-888